Newly FDA-Cleared AI Software Facilitates Advanced Denoising and Accelerated Scan Times for MRI
Enabling up to 80 percent faster MRI scan times, the SubtleHD software is included in the newly launched AI software suite Subtle-Elite.
The Food and Drug Administration (FDA) has granted 510(k) clearance for SubtleHD™, an artificial intelligence (AI) software that reportedly decreases magnetic resonance imaging (MRI) scan times by up to 80 percent for certain sequences.
The SubtleHD software also offers advanced denoising that one can apply for MRI assessment of any body region, according to Subtle Medical, the manufacturer of SubtleHD.
SubtleHD™, an artificial intelligence (AI) software that reportedly enables significant reduction in magnetic resonance imaging (MRI) scan times, has garnered 510(k) clearance from the Food and Drug Administration (FDA). (Images courtesy of Subtle Medical.)
The company is including SubtleHD in a new Subtle-Elite AI software suite that also includes the previously FDA-cleared SubtleSynth, which utilizes deep learning to provide synthetic short tau inversion recovery (STIR) images from T1 and T2-weighted MRI, and SubtleAlign, which provides optimal anatomical alignment for brain MRI scans.
"The FDA clearance of Subtle-HD™ marks a significant milestone in AI-driven radiology, giving hospitals and imaging centers a powerful solution to increase efficiency, improve image quality, and optimize workflows — all without additional hardware costs," noted Ajit Shankaranarayanan, Ph.D., the chief product officer at Subtle Medical. "By combining SubtleHD, SubtleSYNTH, and SubtleALIGN into a single, comprehensive package, Subtle-ELITE™ is setting a new benchmark for the future of MRI."
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
